Medline Alexandra, Joseph Davey Dvora, Klausner Jeffrey D
1 Columbia University Mailman School of Public Health, New York, NY, USA.
2 David Geffen School of Medicine, UCLA, Program in Global Health, Division of Infectious Disease, Los Angeles, CA, USA.
Int J STD AIDS. 2017 Jun;28(7):660-666. doi: 10.1177/0956462416660483. Epub 2016 Jul 20.
Unfavorable pregnancy outcomes caused by Chlamydia trachomatis or Neisseria gonorrhoeae infection are well known. The first step in addressing antenatal C. trachomatis and N. gonorrhoeae infection is a national policy to screen all pregnant women for C. trachomatis and N. gonorrhoeae, regardless of symptoms. The aim of this study was to inform policy makers on the presence of antenatal screening recommendations for C. trachomatis and N. gonorrhoeae infection. We conducted a three-part study from June 2015 to February 2016. We analyzed English and French language information online on Ministry of Health websites regarding C. trachomatis and N. gonorrhoeae antenatal screening. We referenced both primary official country and regional policy documents. We contacted the Ministry of Health directly if the information on the national antenatal screening was outdated or unavailable. In parallel, we sent a survey to the regional representative from the World Health Organization to help collect country-level data. Fourteen countries have current policies for antenatal screening of C. trachomatis and/or N. gonorrhoeae infection: Australia, the Bahamas, Bulgaria, Canada, Estonia, Japan, Germany, Latvia, New Zealand, Democratic People's Republic of Korea, Romania, Sweden, the United Kingdom, and the United States. Australia, New Zealand, and Latvia and the United States restricted antenatal screening to women ≤25 years old and those of higher risk. Several countries responded that they had policies to treat pregnant women with symptoms. This is the currently recommended WHO guideline but is not the same as universal screening. North Korea had policies in place which were not implemented due to lack of personnel and/or supplies. National level policies to support routine screening for C. trachomatis and N. gonorrhoeae infection to prevent adverse pregnancy and newborn outcomes are uncommon.
沙眼衣原体或淋病奈瑟菌感染导致不良妊娠结局是众所周知的。应对产前沙眼衣原体和淋病奈瑟菌感染的第一步是制定一项国家政策，对所有孕妇进行沙眼衣原体和淋病奈瑟菌筛查，无论其有无症状。本研究的目的是让政策制定者了解有关沙眼衣原体和淋病奈瑟菌感染的产前筛查建议的情况。我们在2015年6月至2016年2月期间开展了一项分为三个部分的研究。我们分析了卫生部网站上有关沙眼衣原体和淋病奈瑟菌产前筛查的英文和法文在线信息。我们参考了主要的官方国家和地区政策文件。如果国家产前筛查的信息过时或无法获取，我们直接联系了卫生部。同时，我们向世界卫生组织的地区代表发送了一份调查问卷，以帮助收集国家层面的数据。有14个国家制定了当前的沙眼衣原体和/或淋病奈瑟菌感染产前筛查政策：澳大利亚、巴哈马、保加利亚、加拿大、爱沙尼亚、日本、德国、拉脱维亚、新西兰、朝鲜民主主义人民共和国、罗马尼亚、瑞典、英国和美国。澳大利亚、新西兰、拉脱维亚和美国将产前筛查限制在25岁及以下的女性和高危女性。几个国家回应称，他们有针对有症状孕妇进行治疗的政策。这是世界卫生组织目前推荐的指南，但与普遍筛查不同。朝鲜制定了相关政策，但由于缺乏人员和/或物资而未实施。支持对沙眼衣原体和淋病奈瑟菌感染进行常规筛查以预防不良妊娠和新生儿结局的国家层面政策并不常见。
